DR. TOSAN A FREGENE M.D.
Prescription History 1336189513
Internal Medicine - Hematology & Oncology in Oak Park, MI

NPI Status: Active since June 07, 2006

Contact Information

20770 GREENFIELD RD
STE A
OAK PARK, MI
ZIP 48237
Phone: (249) 967-8800
Fax: (248) 967-0035

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. TOSAN A FREGENE M.D., an active Hematology & Oncology specialist practicing in Oak Park, MI. Our medical registry currently tracks 20 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 673 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 128 claims alone.


Anastrozole

Generic Formulation: AnastrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 128
30-Day Fills 267.5
Days Supply 8,010
MI State Average Benchmarks
Peer Average Claims73.0
Peer Average 30-Day Fills178.7
Peer Average Days Supply5,341
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 75.3% higher than the standard regional baseline profile for MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,879.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$53.75

State Avg Cost Per Claim

$34.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Chlorhexidine Gluconate

Generic Formulation: Chlorhexidine GluconateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 330
MI State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills41.5
Peer Average Days Supply805
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.0% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $38.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.24

State Avg Cost Per Claim

$6.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used along with regular tooth brushing/flossing to treat gingivitis, a gum disease that causes red, swollen, and easily bleeding gums. Chlorhexidine belongs to a class of drugs known as antimicrobials. It works by decreasing the amount of bacteria in the mouth, helping to reduce swelling and redness of the gums and bleeding when you brush.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 30
30-Day Fills 31.8
Days Supply 654
MI State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills34.9
Peer Average Days Supply484
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $575.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.18

State Avg Cost Per Claim

$15.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Eliquis

Generic Formulation: ApixabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 19.0
Days Supply 570
MI State Average Benchmarks
Peer Average Claims76.0
Peer Average 30-Day Fills135.2
Peer Average Days Supply3,873
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.9% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,456.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$881.30

State Avg Cost Per Claim

$879.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Exemestane

Generic Formulation: ExemestaneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 56.0
Days Supply 1,680
MI State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills76.0
Peer Average Days Supply2,271
Conservative Utilization

This provider writes prescriptions for this formulation 39.4% less frequently than the standard regional baseline metric for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,575.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$378.79

State Avg Cost Per Claim

$301.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age.

Hydrochlorothiazide

Generic Formulation: HydrochlorothiazideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
MI State Average Benchmarks
Peer Average Claims69.0
Peer Average 30-Day Fills171.2
Peer Average Days Supply5,118
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.6% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $25.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$2.15

State Avg Cost Per Claim

$5.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.

Therapeutic Applications

This medication is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Hydrochlorothiazide belongs to a class of drugs known as diuretics/water pills. It works by causing you to make more urine. This helps your body get rid of extra salt and water. This medication also reduces extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, or kidney disease. This can lessen symptoms such as shortness of breath or swelling in your ankles or feet.

Hydrocodone-Acetaminophen

Generic Formulation: Hydrocodone/AcetaminophenSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 358
MI State Average Benchmarks
Peer Average Claims94.0
Peer Average 30-Day Fills95.2
Peer Average Days Supply2,065
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 79.8% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $138.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.31

State Avg Cost Per Claim

$19.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to relieve moderate to severe pain. It contains an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen). Hydrocodone works in the brain to change how your body feels and responds to pain. Acetaminophen can also reduce a fever.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 33
30-Day Fills 44.7
Days Supply 1,325
MI State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills70.7
Peer Average Days Supply2,093
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,880.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$56.99

State Avg Cost Per Claim

$38.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Imbruvica

Generic Formulation: IbrutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 51
30-Day Fills 51.0
Days Supply 1,421
MI State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills37.2
Peer Average Days Supply1,053
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 41.7% more claims than the standard regional baseline profile for MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $835,798.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,388.20

State Avg Cost Per Claim

$14,781.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Lenalidomide

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 36
30-Day Fills 36.0
Days Supply 1,008
MI State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.4
Peer Average Days Supply493
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 100.0% higher than the standard regional baseline profile for MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $559,601.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,544.48

State Avg Cost Per Claim

$14,877.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 23.0
Days Supply 690
MI State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills116.3
Peer Average Days Supply3,475
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.0% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $519.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$37.14

State Avg Cost Per Claim

$40.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Morphine Sulfate Er

Generic Formulation: Morphine SulfateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 450
MI State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills46.9
Peer Average Days Supply1,313
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.4% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $411.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$27.43

State Avg Cost Per Claim

$40.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle.

Therapeutic Applications

This medication is used to treat severe pain. Morphine belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 61
30-Day Fills 61.0
Days Supply 711
MI State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.2
Peer Average Days Supply153
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 154.2% higher than the standard regional baseline profile for MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $530.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.70

State Avg Cost Per Claim

$19.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Oxycodone Hcl

Generic Formulation: Oxycodone HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 85
30-Day Fills 85.8
Days Supply 2,163
MI State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills41.3
Peer Average Days Supply733
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 107.3% higher than the standard regional baseline profile for MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,104.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$36.53

State Avg Cost Per Claim

$21.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic derivative of CODEINE.

Therapeutic Applications

This medication is used to help relieve moderate to severe pain. Oxycodone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Oxycontin

Generic Formulation: Oxycodone HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 27
30-Day Fills 29.0
Days Supply 870
MI State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.3
Peer Average Days Supply687
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $62,512.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,315.27

State Avg Cost Per Claim

$815.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic derivative of CODEINE.

Therapeutic Applications

This medication is used to help relieve severe ongoing pain (such as due to cancer). Oxycodone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain. The higher strengths of this drug (more than 40 milligrams per tablet) should be used only if you have been regularly taking moderate to large amounts of an opioid pain medication. These strengths may cause overdose (even death) if taken by a person who has not been regularly taking opioids. Do not use the extended-release form of oxycodone to relieve pain that is mild or that will go away in a few days. This medication is not for occasional (as needed) use.

Oxymorphone Hcl Er

Generic Formulation: Oxymorphone HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 34
30-Day Fills 34.0
Days Supply 1,000
MI State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills21.8
Peer Average Days Supply632
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 61.9% higher than the standard regional baseline profile for MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $55,842.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,642.41

State Avg Cost Per Claim

$908.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An opioid analgesic with actions and uses similar to those of MORPHINE, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092)

Therapeutic Applications

Oxymorphone extended-release is used to help relieve severe ongoing pain. It belongs to a class of drugs known as long-acting opioid analgesics. It works in the brain to change how your body feels and responds to pain. Do not use the extended-release form of oxymorphone to relieve pain that is mild or that will go away in a few days. This medication is not for occasional (as needed) use.

Prednisone

Generic Formulation: PrednisoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 210
MI State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills55.5
Peer Average Days Supply991
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 75.0% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $47.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.35

State Avg Cost Per Claim

$5.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Revlimid

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 476
MI State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills53.5
Peer Average Days Supply1,415
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.9% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $359,753.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$21,161.94

State Avg Cost Per Claim

$18,081.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 39
30-Day Fills 93.0
Days Supply 2,790
MI State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills86.8
Peer Average Days Supply2,593
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,539.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$39.47

State Avg Cost Per Claim

$42.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Xtandi

Generic Formulation: EnzalutamideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 476
MI State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills45.8
Peer Average Days Supply1,360
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.4% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $201,223.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,576.44

State Avg Cost Per Claim

$12,284.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Enzalutamide is used to treat prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. TOSAN A FREGENE M.D. provides transparency into local medical care patterns within Oak Park, MI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.